Voveran pips Corex to emerge best seller
Novartis’ painkiller, Voveran, has emerged as the best-selling drug in the country.
By ET Bureau |
NEW DELHI: Novartis��� painkiller, Voveran, has emerged as the best-selling drug in the country. It has toppled Pfizer���s cough syrup, Corex, for the 12-month period ended May this year in the Rs 33,000-crore domestic retail drug market. During the year, Voveran grew by 13.3% compared to Corex 5.7% in the same period.
According to research-based consultancy firm ORG IMS figures, Voveran posted sales of Rs 14.35 crore for the year-ended May compared to Pfizer drug Corex sales of Rs 14.28 crore. Voveran has been posting highest sales for the monthly sales for the last few months including May also.
Although there can be significant variations in the ranking for monthly sales depending on the prevalence of a particular disease during a period, a 12-month sales figures gives a reliable and larger picture of the sales rankings.
Global pharma companies, despite representing less than one-tenth of the total companies who market their drugs in the country, dominate the list of the top ten selling drugs. Five out of the top ten drugs, including the top three belong to MNCs. Abbott���s anti-diabetic injection, Human Mixtard 30/70, is the third top-selling drug in the country.
Global pharma companies also market much lesser number of drugs than Indian companies. While Cipla and Ranbaxy sell over 807 and 526 drugs, respectively, in the country, Pfizer and Abbott markets just over 100 drugs each.
In the company-wise ranking, domestic major Cipla (5.25%) maintains the top position followed by Ranbaxy Laboratories (5.06%) and UK major GSK (4.62%) for the 12-month period ended May 2008. For May alone, Ranbaxy registered the highest sales with a market share of 5.23% ahead of Cipla���s 5.06%.
According to research-based consultancy firm ORG IMS figures, Voveran posted sales of Rs 14.35 crore for the year-ended May compared to Pfizer drug Corex sales of Rs 14.28 crore. Voveran has been posting highest sales for the monthly sales for the last few months including May also.
Although there can be significant variations in the ranking for monthly sales depending on the prevalence of a particular disease during a period, a 12-month sales figures gives a reliable and larger picture of the sales rankings.
Global pharma companies, despite representing less than one-tenth of the total companies who market their drugs in the country, dominate the list of the top ten selling drugs. Five out of the top ten drugs, including the top three belong to MNCs. Abbott���s anti-diabetic injection, Human Mixtard 30/70, is the third top-selling drug in the country.
Global pharma companies also market much lesser number of drugs than Indian companies. While Cipla and Ranbaxy sell over 807 and 526 drugs, respectively, in the country, Pfizer and Abbott markets just over 100 drugs each.
In the company-wise ranking, domestic major Cipla (5.25%) maintains the top position followed by Ranbaxy Laboratories (5.06%) and UK major GSK (4.62%) for the 12-month period ended May 2008. For May alone, Ranbaxy registered the highest sales with a market share of 5.23% ahead of Cipla���s 5.06%.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
